1cP-LSD

1-Cyclopropionyl-d-lysergic acid diethylamide

1-CPA-LSD, 1-cyclopropanoyl-LSD

Psychoactive Class

Chemical Class

1cP-LSD is a semisynthetic psychedelic of the lysergamide class and an acylated derivative of LSD.¹² It was first developed by Lizard Labs around 2019 as a legal alternative following the anticipated prohibition of 1P-LSD in Germany. It is structurally related to other LSD analogs such as 1P-LSD, 1B-LSD, and ALD-52.¹ Research has demonstrated that it functions as a prodrug of LSD,¹ with anecdotal reports describing near-identical effects.

Dosage & Duration

Dosage

Threshold~10 µg

Light10-50 µg

Moderate50-150 µg

Strong150-300 µg

Heavy300+ µg

Duration

Onset20-60 minutes

Come Up45-120 minutes

Peak3-5 hours

Offset3-5 hours

After Effects6-24 hours

Total8-12 hours

Subjective Effects

Effects vary widely by individual, dose, and context.

Physical

Increased bodily control

Cognitive

In comparison to other psychedelics such as Psilocin, LSA and Ayahuasca, 1cP-LSD is significantly more stimulating and fast paced in terms of the specific style of thought stream which it produces and contains a large number of potential effects.

Enhancement of current mind state Acceleration of thought Feelings of fascination, importance and awe Time distortion Introspection Deja-Vu Multiple thought streams Removal of cultural filter Conceptual thinking Ego suppression, loss and death Personality regression Thought loops Feelings of interdependent opposites Delusions States of unity and interconnectedness

Visual

Distortions

Tracers After images Texture repetition Colour shifting Scenery slicing

Enhancements

Increased visual acuity Enhancement of colours Enhanced pattern recognition

Geometry

The visual geometry of 1cP-LSD can be described as more similar in appearance to that of 2C-B and the 2C-x family than psilocin, LSA, or DMT. They can be comprehensively described as unstructured in organization, algorithmic and digital in geometric style, intricate in complexity, large in size, fast and smooth in motion, multicoloured in scheme, bright and flat in colour, and sharp in their edges with extremely angular corners. At higher dosages they consistently result in states of Level 7A visual geometry.

Hallucinatory States

1cP-LSD is capable of producing a full range of low and high level hallucinatory states in a fashion that is significantly less consistent and reproducible than that of many other commonly used psychedelics.

External hallucinations

Auditory

Enhancements Distortions Hallucinations

Adapted from the LSD subjective effects documentation. 1cP-LSD is a prodrug of LSD and is reported to produce an effectively identical experience. Forked from Subjective Effect Documentation

by Josie KinsOctober 2012.

Reagent Testing

Loading reagent data

Expected colorimetric results are being prepared.

Pharmacology

Pharmacodynamics

1cP-LSD is a prodrug of LSD, with its psychedelic effects mediated through the activity of LSD at serotonin 5-HT2A receptors, where it acts as a partial agonist.¹¹ In rodent studies, 1cP-LSD produces the head-twitch response (a behavioral marker of 5-HT2A receptor activation) with potency comparable to 1P-LSD.¹ Direct pharmacological characterization of 1cP-LSD at specific receptor targets remains limited.

Pharmacokinetics

1cP-LSD undergoes metabolic conversion to LSD, which serves as its pharmacologically active form.¹ Specific details regarding the enzymes responsible for this conversion, oral bioavailability, and elimination half-life have not been characterized in the available literature.

Interactions

Dangerous

Highest risk

These combinations are considered extremely harmful and should always be avoided. Reactions to these drugs taken in combination are highly unpredictable and have a potential to cause death.

Lithium

Unsafe

Avoid

There is considerable risk of physical harm when taking these combinations, they should be avoided where possible.

Tramadol

Caution

Use caution

These combinations are not usually physically harmful, but may produce undesirable effects, such as physical discomfort or overstimulation. Extreme use may cause physical health issues. Synergistic effects may be unpredictable. Care should be taken when choosing to use this combination.

AmphetaminesCannabisCocaineDiphenhydramineMephedronePregabalin

TripSit

Tolerance

Full Tolerance

Develops almost immediately after ingestion.

Baseline Reset

14 days

Half Tolerance

5-7 days

Cross Tolerance

Serotonergic psychedelics

Harm Potential

Addiction & Dependence

Psychological

Extremely Low

Presumed to be non-addictive with low abuse potential, similar to LSD. Animal studies with LSD show no self-administration behavior, indicating it lacks the pharmacology to initiate or maintain dependence.³

Physical

Extremely Low

Virtually no withdrawal syndrome is reported when chronic use of LSD or its analogs is stopped, suggesting 1cP-LSD carries minimal physical dependence potential.⁴

Psychosis Risk

May act as a trigger for psychotic episodes in individuals with underlying mental disorders or a family history of mental illness.⁴ Higher doses increase the risk of adverse psychological reactions, including anxiety, delusions, and panic attacks. People with a personal or family history of mental illness are generally advised to avoid using this substance.

Seizure Risk

Seizure risk is largely extrapolated from LSD reports and is primarily a concern for those genetically predisposed, particularly when accompanied by physically taxing conditions such as dehydration, fatigue, undernourishment, or overheating.⁵

History & Culture

1cP-LSD was developed by Lizard Labs, a research chemical laboratory based in the Netherlands, as a legal alternative to LSD. The compound emerged on the grey market around 2019, reportedly created in anticipation of the impending prohibition of 1P-LSD in Germany. Like its predecessor, 1cP-LSD is…

Trip Reports

Legality

By Country

CanadaUnscheduled

Not listed as a controlled substance under Canadian drug control legislation. Remains legal to possess and purchase.

GermanyControlled (NpSG)

Regulated under the Neue-psychoaktive-Stoffe-Gesetz (New Psychoactive Substances Act) as of July 2, 2021.⁹ Production and importation with intent to distribute, administration to others, and commercial trading are criminal offenses. Possession is prohibited but carries no penalty. Prior to this date, 1cP-LSD existed in a legal grey area as its cyclopropylcarbonyl group was not considered an alkyl radical under the original NpSG amendment regulation.

SwedenDangerous substance

Sweden's public health agency proposed classification as a dangerous substance on December 18, 2019. Formally classified as such on April 22, 2021.

United KingdomControlled (PSA)

Covered by the Psychoactive Substances Act 2016,¹⁰ effective May 26, 2016.¹¹ Production, supply, and importation are criminal offenses. Personal possession is not penalized under this legislation, though the substance cannot be legally sold for human consumption.

Czech RepublicUncontrolled

Not designated as a controlled substance and does not appear on the national list of prohibited drugs.

JapanControlled

Regulated under the Pharmaceutical Affairs Law. Both possession and sale are prohibited.

TurkeyIllegal

Classified as a controlled drug. Possession, production, supply, and importation are all criminal offenses.

References

Source Pages

Citations

Suggest an edit

Spotted a mistake, an outdated claim, or something missing from the 1cP-LSD article? Send the editors a private note. Feedback lands in a moderation queue and is never shown on the site.

1cP-LSD

1-Cyclopropionyl-d-lysergic acid diethylamide

1-CPA-LSD, 1-cyclopropanoyl-LSD

Psychoactive Class

Psychedelic

Chemical Class

Lysergamide